VRTX JPM 2026 Presentation_vFINAL.pdf

1、2026 Vertex Pharmaceuticals Incorporated2026 Vertex Pharmaceuticals IncorporatedJ.P.Morgan Healthcare ConferenceJanuary 2026Reshma Kewalramani,M.D.CEO and President2Safe Harbor Statement&Non-GAAP Financial MeasuresThis presentation contains forward-looking statements as defined in the Private Securi

2、ties Litigation Reform Act of 1995,including,without limitation,the information provided regarding future financial and operating performance and statements regarding(i)expectations,goals,development and commercialization plans and timelines for the companys products,product candidates and pipeline

3、programs,including beliefs regarding the emerging renal business,multiple launch opportunities,treatable patient populations,and additional opportunities in mid-and-late stage programs,including more than 10 disease areas with multi-billion dollar market potential,(ii)expectations for sustained grow

4、th with respect to the companys CF medicines,including with respect to the ongoing commercial launch of ALYFTREK,that the majority of eligible CF patients will switch from TRIKAFTA to ALYFTREK over time,treating younger patients,filing for approval for TRIKAFTA in patients 1 to 2 years of age in H1

5、2026 and securing approval in H2 2026,sharing data from Phase 3 study of ALYFTREK in patients 2 to 5 years of age and submitting for regulatory approval in 2026,initiating a Phase 3 study of ALYFTREK in patients 1 to 2 years of age in 2026,CF population growth and patients living longer,reaching add

6、itional geographies,the goal to advance additional small molecules to be able to bring all eligible patients to carrier levels of CFTR function,and extending the CF portfolios market leadership with IP through 2040,(iii)plans to advance VX-522 to reach the 5,000 CF patients who cannot benefit from a